leadf
logo-loader
viewCytoDyn Inc.
(
OTCQB:CYDY
)

CytoDyn expects to exceed 75-patient enrollment in its coronavirus-focused Phase 2 clinical trial

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive its expects to exceed its 75 patient enrollment for a Phase 2 clinical trial of leronlimab for patients with mild-to-moderate symptoms of COVID-19.

Nader says the Washington-based biotech expects the evaluation of clinical patient data to be available two weeks after the last patient is enrolled. He also updated on its Phase 3 coronavirus-focused study.

Quick facts: CytoDyn Inc.

Follow
OTCQB:CYDY

Price: 2.01 USD

Market Cap: $1.27 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

CytoDyn treats first patient with flagship drug in its Phase 3 coronavirus...

CytoDyn Inc CEO Nader Pourhassan tells Proactive it has treated the first patient with its flagship drug candidate leronlimab (Vyrologix or PRO 140) in a pivotal Phase 3 coronavirus trial in Brazil for patients with severe symptoms. Pourhassan says an interim analysis will be conducted 28...

1 week, 2 days ago

2 min read